A randomized, placebo-controlled trial demonstrated that liraglutide 3.0 mg significantly combats weight regain after Roux-en-Y gastric bypass, with 76% of subjects achieving at least a 5% total body weight loss compared to 17% in the placebo group. Notably, 21% of liraglutide recipients exceeded their postoperative nadir weight. Throughout the study, nonserious adverse events were reported in 41.6% of liraglutide users, while serious adverse events occurred less frequently, highlighting its safety profile in this context.
Journal Article by Lofton HF, Maranga G (…) Fielding C et 5 al. in Surg Obes Relat Dis
Copyright © 2024 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.